Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.

Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, et al. DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051-1063.

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.

Butler DJ, Mozsary C, Meydan C, Danko D, Foox J, Rosiene J, et al. Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions. bioRxiv. 2020.

Cantu MD, Towne WS, Emmons FN, Mostyka M, Borczuk A, Salvatore SP, et al. Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients. Br J Haematol. 2020;190(2):e89-e92.

Zhou P, Yan F. CRL4 Ubiquitin Pathway and DNA Damage Response. Adv Exp Med Biol. 2020;1217:225-239.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25(2):140-149.

Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife. 2020;9.

Strother RM, Gopal S, Wirth M, Chadburn A, Noy A, Cesarman E, et al. Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study. JCO Glob Oncol. 2020;6:1034-1040.